Servier’s Asparlas (calaspargase pegol-mknl) Receives FDA’s Approval for Acute Lymphoblastic Leukemia (ALL)

 Servier’s Asparlas (calaspargase pegol-mknl) Receives FDA’s Approval for Acute Lymphoblastic Leukemia (ALL)

Servier’s Asparlas (calaspargase pegol-mknl) Receives FDA’s Approval for Acute Lymphoblastic Leukemia (ALL)

Shots:

  • The approval is based on study assessing Asparlas (2500 U/m2, IV, q3w) in combination with multiagent chemotherapy in 124 patients with B-cell lineage ALL
  • The study resulted in achievement and maintenance of nadir serum asparaginase activity above the level of 0.1 U/mL
  • Asparlas (calaspargase pegol-mknl, IV) is an asparagine specific enzyme approved as a combination therapy for patients with ALL aged 1 month to 21 yr

Click here to read full press release/ article | Ref: The US FDA | Image: WSJ

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post